Docoh
Loading...

CRXM Gene Biotherapeutics

Filed: 9 Aug 21, 4:58pm

 

EXHIBIT 16.1

 

 

FORM 8-K ATTACHMENT - CHANGE OF ACCOUNTANTS’ LETTER

 

August 6, 2021

Securities and Exchange

Commission 100 F Street, N.E.

Washington, DC 20549

 

Commissioners:

 

We have read the statements made by Gene Biotherapeutics, Inc. under Item 4.01 of its Form 8- K dated August 6, 2021 We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Gene Biotherapeutics, Inc. contained therein.

 

Very truly yours,

 

 Marcum LLP